Skip to main content

Immuneering Corp

IMRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001790340

No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Immuneering Corp changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of IMRX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders4952+3
Shares17.3M16.9M−329.2K (−1.9%)
Value$175.9M$130.1M−$45.8M (−26.0%)

New holders (7)

Institutions that held Immuneering Corp at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to IMRX in Q3 2023
InstitutionSharesValue% of portfolio
HighTower Advisors, LLC23,960$184.0K0.00%
The PNC Financial Services Group, Inc.20,000$153.6K0.00%
Corton Capital Inc.18,847$144.7K0.07%
Southport Management, L.L.C.17,500$134.4K0.73%
Dimensional Fund Advisors LP16,684$128.1K0.00%
American Century Companies Inc11,450$87.9K0.00%
Harbour Investments, Inc.25$1920.00%

Sold out (4)

Institutions that held Immuneering Corp at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of IMRX in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Bank of Montreal714,037$8.00M
Tucker Asset Management LLC11,036$111.9K
Cary Street Partner Investment Advisory LLC301$3.05K
Zurcher Kantonalbank (Zurich Cantonalbank)5$51